Several preclinical studies suggested a potential benefit from combined treatment with
inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in …

The recently developed'targeted'therapies, epidermal growth factor receptor (EGFR)
inhibitors and angiogenesis inhibitors, target specific tumour characteristics. EGFR …

Standard first-line therapy for non–small-cell lung cancer (NSCLC) with platinum-based
agents, given in combination with cytotoxic compounds, has reached a relative plateau in its …

Elucidation of molecular pathways that promote malignancies has led to the identification of
the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) …

Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase
inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular …

9569 Background: Erlotinib is indicated in first line treatment for patients with Non-Small-Cell-
Lung cancer (NSCLC) harbouring EGFR mutation. Addition of anti-VEGF in combination …

Inhibition of the epidermal growth factor receptor (EGFR) has become a standard target in
the treatment of non-small cell lung cancer (NSCLC). This chapter summarizes the clinical …

Purpose Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …

Non-small cell lung cancer (NSCLC) is a major global health problem and represents the
leading cause of cancer-related deaths worldwide. The majority of patients with NSCLC are …

Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …